Rapt Therapeutics (RAPT) Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Is AMLX or RAPT more profitable?

Rapt Therapeutics' return on equity of -67.92% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-82.48%	-70.15%
Rapt Therapeutics	N/A	-67.92%	-59.59%

Which has preferable valuation and earnings, AMLX or RAPT?

Rapt Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	8.58	-$301.74M	-$2.50	-3.36
Rapt Therapeutics	$1.53M	121.62	-$129.87M	-$14.17	-0.79

Which has more volatility and risk, AMLX or RAPT?

Amylyx Pharmaceuticals has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Does the media favor AMLX or RAPT?

In the previous week, Rapt Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for Rapt Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Rapt Therapeutics' average media sentiment score of 0.35 beat Amylyx Pharmaceuticals' score of 0.27 indicating that Rapt Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapt Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in AMLX or RAPT?

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer AMLX or RAPT?

Amylyx Pharmaceuticals currently has a consensus target price of $11.75, indicating a potential upside of 39.71%. Rapt Therapeutics has a consensus target price of $21.57, indicating a potential upside of 91.75%. Given Rapt Therapeutics' higher possible upside, analysts clearly believe Rapt Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rapt Therapeutics	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Rapt Therapeutics beats Amylyx Pharmaceuticals on 10 of the 16 factors compared between the two stocks.